Dr Katrin Sjoquist

Senior Research Fellow
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 95625025
Fax +61 2 95651863

Website Related website

Map

Biographical details

Dr Sjoquist is a qualified Medical Oncologist and clinical researcher.

Research interests

Design & management of Phase II/III Clinical Trials, evidence based medicine, Gastrointestinal & Gynaecological Cancers, evaluating benefits versus harms of treatment

Selected grants

2014

  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Shannon C, Martyn J, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms; Friedlander M, Sjoquist K, Beale P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101); Friedlander M, Sjoquist K, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • Value of serum levels of Inhibin A, inhibin B, total inhibin and anti- Mullerian Hormone ( AMH) in measuring response of recurrent Granulosa cell tumours to Anastrazole; Friedlander M, Sjoquist K, Robertson D, BURGER H, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer; Friedlander M, Quinn M, Mileshkin L, Ledermann J, Clamp A, Dean A, Beale P, Sjoquist K, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative.; Brand A, Friedlander M, Stockler M, Sjoquist K, Gebski V; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2012

  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2011

  • Study to evaluate the safety and efficacy of intraperitoneal bevacizumab in patients with advanced platinum refractory or resistant ovarian cancer and symptomatic ascites; Friedlander M, Sjoquist K, Martyn J; DVC Research/Cancer Research Fund.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Sjoquist, K., Chin, V., Chantrill, L., OConnor, C., Hemmings, C., Chang, D., Chou, A., Pajic, M., Johns, A., Nagrial, A., et al (2014). Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 20(24), 7849-7863. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
  • Sjoquist, K., Zalcberg, J. (2013). Clinical Trials - Advancing National Cancer Care. Cancer Forum, 37(1), 80-87.
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Sommeijer, D., Sjoquist, K., Friedlander, M. (2013). Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature. Current Oncology Reports, 15(6), 541-548. [More Information]
  • Cameron, A., Sjoquist, K., Zalcberg, J. (2011). Overview of controversies in oesophagogastric cancer. Cancer Forum, 35(3), 139-141.
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]
  • Sjoquist, K., Goldstein, D., Bester, L. (2010). A serious complication of selected internal radiation therapy: case report and literature review. The Oncologist, 15(8), 830-835. [More Information]

Conferences

  • Rao, A., Hui, A., Barton, M., Sjoquist, K. (2011). Benefits and Harms of Radiotherapy for Rectal Cancer: Meta-analysis of survival and toxicity. Medical Oncology Group of Australia Limited Annual Scientific Meeting 2011, Adelaide, South Australia: Medical Oncology Group of Australia.

2014

  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Sjoquist, K., Chin, V., Chantrill, L., OConnor, C., Hemmings, C., Chang, D., Chou, A., Pajic, M., Johns, A., Nagrial, A., et al (2014). Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 20(24), 7849-7863. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]

2013

  • Sjoquist, K., Zalcberg, J. (2013). Clinical Trials - Advancing National Cancer Care. Cancer Forum, 37(1), 80-87.
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Sommeijer, D., Sjoquist, K., Friedlander, M. (2013). Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature. Current Oncology Reports, 15(6), 541-548. [More Information]

2011

  • Rao, A., Hui, A., Barton, M., Sjoquist, K. (2011). Benefits and Harms of Radiotherapy for Rectal Cancer: Meta-analysis of survival and toxicity. Medical Oncology Group of Australia Limited Annual Scientific Meeting 2011, Adelaide, South Australia: Medical Oncology Group of Australia.
  • Cameron, A., Sjoquist, K., Zalcberg, J. (2011). Overview of controversies in oesophagogastric cancer. Cancer Forum, 35(3), 139-141.
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]

2010

  • Sjoquist, K., Goldstein, D., Bester, L. (2010). A serious complication of selected internal radiation therapy: case report and literature review. The Oncologist, 15(8), 830-835. [More Information]

To update your profile click here. For support on your academic profile contact .